Methods of incorporating amino acid analogs into proteins -> Monitor Keywords
Fresh Patents
Monitor Patents Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents Browse Locations
site info Site News  |  monitor Monitor Keywords  |  monitor archive Monitor Archive  |  organizer Organizer  |  account info Account Info  |  
12/29/05 - USPTO Class 435 |  54 views | #20050287639 | Prev - Next | About this Page  435 rss/xml feed  monitor keywords

Methods of incorporating amino acid analogs into proteins

USPTO Application #: 20050287639
Title: Methods of incorporating amino acid analogs into proteins
Abstract: The invention provides a method of incorporating nonstandard amino acids into a protein by utilizing a modified aminoacyl-tRNA synthetase to charge the nonstandard amino acid to a modified tRNA, which forms strict Watson-Crick base-pairing with a codon that normally forms wobble base-pairing with natural tRNAs. (end of abstract)



Agent: Fish & NeaveIPGroup Ropes & Gray LLP - Boston, MA, US
Inventors: Inchan Kwon, David Tirrell
USPTO Applicaton #: 20050287639 - Class: 435069100 (USPTO)

Related Patent Categories: Chemistry: Molecular Biology And Microbiology, Micro-organism, Tissue Cell Culture Or Enzyme Using Process To Synthesize A Desired Chemical Compound Or Composition, Recombinant Dna Technique Included In Method Of Making A Protein Or Polypeptide

Methods of incorporating amino acid analogs into proteins description/claims


The Patent Description & Claims data below is from USPTO Patent Application 20050287639, Methods of incorporating amino acid analogs into proteins.

Brief Patent Description - Full Patent Description - Patent Application Claims
  monitor keywords



REFERENCE TO RELATED APPLICATION

[0001] This application claims the benefit of the filing date of U.S. Provisional Application 60/571,810, filed on May 17, 2004, the entire content of which is incorporated herein by reference.

BACKGROUND OF THE INVENTION

[0003] Protein engineering is a powerful tool for modification of the structural catalytic and binding properties of natural proteins and for the de novo design of artificial proteins. Protein engineering relies on an efficient recognition mechanism for incorporating mutant amino acids in the desired protein sequences. Though this process has been very useful for designing new macromolecules with precise control of composition and architecture, a major limitation is that the mutagenesis is restricted to the 20 naturally occurring amino acids. However, it is becoming increasingly clear that incorporation of unnatural amino acids can extend the scope and impact of protein engineering methods. Thus, for many applications of designed macromolecules, it would be desirable to develop methods for incorporating amino acids that have novel chemical functionality not possessed by the 20 amino acids commonly found in naturally occurring proteins. That is, ideally, one would like to tailor changes in a protein (the size, acidity, nucleophilicity, hydrogen-bonding or hydrophobic properties, etc. of amino acids) to fulfill a specific structural or functional property of interest. The ability to incorporate such amino acid analogs into proteins would greatly expand our ability to rationally and systematically manipulate the structures of proteins, both to probe protein function and create proteins with new properties. For example, the ability to synthesize large quantities of proteins containing heavy atoms would facilitate protein structure determination, and the ability to site specifically substitute fluorophores or photo-cleavable groups into proteins in living cells would provide powerful tools for studying protein functions in vivo. One might also be able to enhance the properties of proteins by providing building blocks with new functional groups, such as an amino acid containing a keto-group.

[0004] Incorporation of novel amino acids in macromolecules has been successful to an extent. Biosynthetic assimilation of non-canonical amino acids into proteins has been achieved largely by exploiting the capacity of the wild type synthesis apparatus to utilize analogs of naturally occurring amino acids (Budisa 1995, Eur. J. Biochem 230: 788-796; Deming 1997, J Macromol. Sci. Pure Appl. Chem A34; 2143-2150; Duewel 1997, Biochemistry 36: 3404-3416; van Hest and Tirrell 1998, FEBS Lett 428(1-2): 68-70; Sharma et al., 2000, FEBS Lett 467(1): 37-40). Nevertheless, the number of amino acids shown conclusively to exhibit translational activity in vivo is small, and the chemical functionality that has been accessed by this method remains modest. In designing macromolecules with desired properties, this poses a limitation since such designs may require incorporation of complex analogs that differ significantly from the natural substrates in terms of both size and chemical properties and hence, are unable to circumvent the specificity of the synthetases. Thus, there is a need to develop a method to further expand the range of unnatural amino acids that can be incorporated.

[0005] In recent years, several laboratories have pursued an expansion in the number of genetically encoded amino acids, by using either a nonsense suppressor or a frame-shift suppressor tRNA to incorporate non-canonical amino acids into proteins in response to amber or four-base codons, respectively (Bain et al., J. Am. Chem. Soc. 111: 8013, 1989; Noren et al., Science 244: 182, 1989; Furter, Protein Sci. 7:419, 1998; Wang et al., Proc. Natl. Acad. Sci. U.S.A., 100: 56, 2003; Hohsaka et al., FEBS Lett. 344: 171: 1994; Kowal and Oliver, Nucleic Acids Res. 25: 4685, 1997). Such methods insert non-canonical amino acids at codon positions that will normally terminate wild-type peptide synthesis (e.g. a stop codon or a frame-shift mutation). These methods have worked well for single-site insertion of novel amino acids. However, their utility in multisite incorporation is limited by modest (20-60%) suppression efficiencies (Anderson et al., J. Am. Chem. Soc. 124: 9674, 2002; Bain et al., Nature 356: 537, 1992; Hohsaka et al., Nucleic Acids Res. 29: 3646, 2001). This is so partially because too high a stop codon suppression efficiency will interfere with the normal translation termination of some non-targeted proteins in the organism. On the other hand, a low suppression efficiency will likely be insufficient to suppress more than one nonsense or frame-shift mutation sites in the target protein, such that it becomes more and more difficult or impractical to synthesize a full-length target protein incorporating more and more non-canonical amino acids.

[0006] Efficient multisite incorporation has been accomplished by replacement of natural amino acids in auxotrophic Escherichia coli strains, and by using aminoacyl-tRNA synthetases with relaxed substrate specificity or attenuated editing activity (Wilson and Hatfield, Biochim. Biophys. Acta 781: 205, 1984; Kast and Hennecke, J. Mol. Biol. 222: 99, 1991; Ibba et al., Biochemistry 33: 7107, 1994; Sharma et al., FEBS Lett. 467: 37, 2000; Tang and Tirrell, Biochemistry 41: 10635, 2002; Datta et al., J. Am. Chem. Soc. 124: 5652, 2002; Doring et al., Science 292: 501, 2001). Although this method provides efficient incorporation of analogues at multiple sites, it suffers from the limitation that the novel amino acid must "share" codons with one of the natural amino acids. Thus for any given codon position where both natural and novel amino acids can be inserted, other than a probability of incorporation, there is relatively little control over which amino acid will end up being inserted. This may be undesirable, since for an engineered enzyme or protein, non-canonical amino acid incorporation at an unintended site may unexpectedly compromise the function of the protein, while missing incorporating the non-canonical amino acid at the designed site will fail to achieve the design goal.

[0007] The invention provides a new technique for the incorporation of non-standard/non-canonical amino acids into proteins that is based on breaking the degeneracy of the genetic code.

SUMMARY OF THE INVENTION

[0008] The present invention provides compositions of components used in protein biosynthetic machinery, which include orthogonal tRNA/aminoacyl-tRNA synthetase (AARS) pairs and the individual components of the pairs. Methods for generating and selecting orthogonal tRNAs, orthogonal aminoacyl-tRNA synthetases, and pairs thereof that can use an unnatural amino acid are also provided. Compositions of the invention include novel orthogonal tRNA/aminoacyl-tRNA synthetase pairs. The novel orthogonal pairs can be use to incorporate an unnatural amino acid in a polypeptide in vitro and in vivo. Other embodiments of the invention include selecting orthogonal pairs.

[0009] Compositions of the present invention include an orthogonal aminoacyl-tRNA synthetase (O-RS), where the O-RS preferentially aminoacylates an orthogonal tRNA (O-tRNA) with an unnatural amino acid, optionally, in vivo. In one embodiment, the invention provides a nucleic acid encoding an O-RS, or a complementary nucleic acid sequence thereof. In another embodiment, the O-RS has improved or enhanced enzymatic properties, e.g., the K.sub.m is higher or lower, the k.sub.cat, is higher or lower, the value of k.sub.cat/K.sub.m is higher or lower or the like, for the unnatural amino acid compared to a naturally occurring amino acid, e.g., one of the 20 known amino acids.

[0010] Thus one aspect of the invention relates to a polynucleotide encoding a modified tRNA of a tRNA for a natural amino acid, wherein the natural amino acid is encoded by one or more wobble degenerate codon(s), the modified tRNA comprises a modified anticodon sequence that forms Watson-Crick base-pairing with one of the wobble degenerate codon(s). Preferably, the modified tRNA is not or only inefficiently charged by an endogenous aminoacyl-tRNA synthetase (AARS) for the natural amino acid.

[0011] In certain embodiments, the modified tRNA interacts with the wobble degenerate codon with an affinity at 37.degree. C. of at least about 1.0 kcal/mole, or 1.5 kcal/mole, or even 2.0 kcal/mole more favorably than the interaction between its unmodified version and the wobble degenerate codon.

[0012] In certain embodiments, the modified tRNA can be efficiently charged to carry an analog of the natural amino acid (e.g. the unnatural amino acid).

[0013] In certain embodiments, the unnatural amino acid is a derivative of at least one of the 20 natural amino acids, with one or more functional groups not present in natural amino acids.

[0014] In certain embodiments, the functional group is selected from the group consisting of: bromo-, iodo-, ethynyl-, cyano-, azido-, acetyl, aryl ketone, a photolabile group, a fluorescent group, and a heavy metal.

[0015] In certain embodiments, the unnatural amino acid is any one of those described herein or known in the art, such as any one in FIGS. 29, 30, and 31 of U.S. 2003/0108885 A1 (entire content incorporated herein by reference).

[0016] In certain embodiments, the amino acid analog is a derivative of Phe, such as NaI.

[0017] In certain embodiments, the amino acid analog is a derivative of Trp, such as 6-bromo-L-tryptophan, 6-chloro-L-tryptophan, or Benzothienyl-L-alanine (Sulfur instead of Nitrogen in tryptophan).

[0018] In certain embodiments, the modified tRNA, when charged with the unnatural amino acid, can be incorporated by a translation system into a polypeptide comprising the wobble degenerate codon.

[0019] In certain embodiments, the modified AARS with relaxed substrate specificity charges the modified tRNA with the unnatural amino acid.

[0020] In certain embodiments, the specificity constant (k.sub.cat/K.sub.M) for activation of the unnatural amino acid by the modified AARS is at least 5-fold larger than that for the natural amino acid.

[0021] In certain embodiments, the tRNA is tRNA.sup.Phe, the degenerate codon is UUU, and the analog is L-3-(2-naphthyl)alanine (NaI).

[0022] In certain embodiments, the modified tRNA further comprises a mutation at the fourth, extended anticodon site for increase translational efficiency.

Continue reading about Methods of incorporating amino acid analogs into proteins...
Full patent description for Methods of incorporating amino acid analogs into proteins

Brief Patent Description - Full Patent Description - Patent Application Claims

Click on the above for other options relating to this Methods of incorporating amino acid analogs into proteins patent application.
###
monitor keywords

How KEYWORD MONITOR works... a FREE service from FreshPatents
1. Sign up (takes 30 seconds). 2. Fill in the keywords to be monitored.
3. Each week you receive an email with patent applications related to your keywords.  
Start now! - Receive info on patent apps like Methods of incorporating amino acid analogs into proteins or other areas of interest.
###


Previous Patent Application:
Hyaluronan receptor for endocytosis, variants thereof, and methods of making and using same
Next Patent Application:
Novel genes of cell wall-degrading enzymes derived from aspergillus, and method for the production the enzymes
Industry Class:
Chemistry: molecular biology and microbiology

###

FreshPatents.com Support
Thank you for viewing the Methods of incorporating amino acid analogs into proteins patent info.
IP-related news and info


Results in 0.17875 seconds


Other interesting Feshpatents.com categories:
Computers:  Graphics I/O Processors Dyn. Storage Static Storage Printers 174
filepatents (1K)

* Protect your Inventions
* US Patent Office filing
patentexpress PATENT INFO